Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG 60 Debt-to-EBITDA is -4.13 as of Dec. 2025. GuruFocus rates XMAD:PANG with a GF Score™ of 60/100 and a GF Value™ of €2.23 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 884954.87% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pangaea Oncology's Debt-to-EBITDA or its related term are showing as below:
XMAD:PANG'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -39.01 Med: -3.38 Max: 33.27
Current: -6.16
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pangaea Oncology was 33.27. The lowest was -39.01. And the median was -3.38.
XMAD:PANG's Debt-to-EBITDA is ranked worse than 100% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.34
vs XMAD:PANG: -6.16
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pangaea Oncology Debt-to-EBITDA Related Terms
Pangaea Oncology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Pangaea Oncology (XMAD:PANG) has a Debt-to-EBITDA of -4.13 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pangaea Oncology. According to the industry distribution chart, Pangaea Oncology ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry.
Is Pangaea Oncology's Debt-to-EBITDA too high?
Pangaea Oncology's current Debt-to-EBITDA is -4.13. Based on the distribution chart, Pangaea Oncology ranks #999999 out of 113 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #999999 out of 113 companies for Debt-to-EBITDA. This places Pangaea Oncology in the lower half of its industry. The industry median Debt-to-EBITDA is 2.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.34, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pangaea Oncology. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Debt-to-EBITDA is -4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.23, compared to a current price of €1.55 — trading 30.5% below its estimated fair value. The current Debt-to-EBITDA is -4.13. Pangaea Oncology's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Debt-to-EBITDA is -4.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.55 is trading 30.5% below its estimated GF Value™ of €2.23.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Debt-to-EBITDA: -4.13
GF Value™: €2.23 vs. price of €1.55 (30.5% below fair value)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score
Get the complete analysis for XMAD:PANG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
